These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 26600904)

  • 21. Detection of lipoarabinomannan (LAM) in urine is an independent predictor of mortality risk in patients receiving treatment for HIV-associated tuberculosis in sub-Saharan Africa: a systematic review and meta-analysis.
    Gupta-Wright A; Peters JA; Flach C; Lawn SD
    BMC Med; 2016 Mar; 14():53. PubMed ID: 27007773
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Rapid Urine LAM Testing Improves Diagnosis of Expectorated Smear-Negative Pulmonary Tuberculosis in an HIV-endemic Region.
    Drain PK; Gounder L; Sahid F; Moosa MY
    Sci Rep; 2016 Feb; 6():19992. PubMed ID: 26865526
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Diagnosing tuberculosis in hospitalized HIV-infected individuals who cannot produce sputum: is urine lipoarabinomannan testing the answer?
    Sabur NF; Esmail A; Brar MS; Dheda K
    BMC Infect Dis; 2017 Dec; 17(1):803. PubMed ID: 29282005
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Value of urine lipoarabinomannan grade and second test for optimizing clinic-based screening for HIV-associated pulmonary tuberculosis.
    Drain PK; Losina E; Coleman SM; Giddy J; Ross D; Katz JN; Bassett IV
    J Acquir Immune Defic Syndr; 2015 Mar; 68(3):274-80. PubMed ID: 25415288
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Diagnostic accuracy of a novel tuberculosis point-of-care urine lipoarabinomannan assay for people living with HIV: A meta-analysis of individual in- and outpatient data.
    Broger T; Nicol MP; Székely R; Bjerrum S; Sossen B; Schutz C; Opintan JA; Johansen IS; Mitarai S; Chikamatsu K; Kerkhoff AD; Macé A; Ongarello S; Meintjes G; Denkinger CM; Schumacher SG
    PLoS Med; 2020 May; 17(5):e1003113. PubMed ID: 32357197
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Predictors and outcomes of mycobacteremia among HIV-infected smear- negative presumptive tuberculosis patients in Uganda.
    Nakiyingi L; Ssengooba W; Nakanjako D; Armstrong D; Holshouser M; Kirenga BJ; Shah M; Mayanja-Kizza H; Joloba ML; Ellner JJ; Dorman SE; Manabe YC
    BMC Infect Dis; 2015 Feb; 15():62. PubMed ID: 25888317
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Utility of the lateral flow urine lipoarabinomannan tuberculosis assay in patients with advanced HIV disease at antiretroviral therapy centres in Mumbai, India.
    Acharya S; Deshpande P; Asirvatham ES; Palkar A; Sarman CJ; Laxmeshwar C; Setia MS; Rathod D; Koli S; Dale J; Yeldandi V; Allam R; Agarwal R; Verma S; Upadhyaya S; Nyendak M
    PLoS One; 2022; 17(9):e0273970. PubMed ID: 36103506
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Incidence of Tuberculosis Among HIV-Positive Individuals Initiating Antiretroviral Treatment at Higher CD4 Counts in the HPTN 071 (PopART) Trial in South Africa.
    Bock P; Jennings K; Vermaak R; Cox H; Meintjes G; Fatti G; Kruger J; De Azevedo V; Maschilla L; Louis F; Gunst C; Grobbelaar N; Dunbar R; Limbada M; Floyd S; Grimwood A; Ayles H; Hayes R; Fidler S; Beyers N
    J Acquir Immune Defic Syndr; 2018 Jan; 77(1):93-101. PubMed ID: 29016524
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Does the use of adjunct urine lipopolysaccharide lipoarabinomannan in HIV-infected hospitalized patients reduce the utilization of healthcare resources? A post hoc analysis of the LAM multi-country randomized controlled trial.
    Naidoo P; Esmail A; Peter JG; Davids M; Fadul M; Dheda K
    Int J Infect Dis; 2019 Feb; 79():37-43. PubMed ID: 30292891
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Diagnostic accuracy of a urine lipoarabinomannan test for tuberculosis in hospitalized patients in a High HIV prevalence setting.
    Shah M; Variava E; Holmes CB; Coppin A; Golub JE; McCallum J; Wong M; Luke B; Martin DJ; Chaisson RE; Dorman SE; Martinson NA
    J Acquir Immune Defic Syndr; 2009 Oct; 52(2):145-51. PubMed ID: 19692904
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical utility of a commercial LAM-ELISA assay for TB diagnosis in HIV-infected patients using urine and sputum samples.
    Dheda K; Davids V; Lenders L; Roberts T; Meldau R; Ling D; Brunet L; van Zyl Smit R; Peter J; Green C; Badri M; Sechi L; Sharma S; Hoelscher M; Dawson R; Whitelaw A; Blackburn J; Pai M; Zumla A
    PLoS One; 2010 Mar; 5(3):e9848. PubMed ID: 20352098
    [TBL] [Abstract][Full Text] [Related]  

  • 32. CD4+ cell count responses to antiretroviral therapy are not impaired in HIV-infected individuals with tuberculosis co-infection.
    Gupta RK; Brown AE; Zenner D; Rice B; Yin Z; Thomas HL; Pozniak A; Abubakar I; Delpech V; Lipman M
    AIDS; 2015 Jul; 29(11):1363-8. PubMed ID: 26091298
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Diagnostic accuracy of a urine lipoarabinomannan enzyme-linked immunosorbent assay for screening ambulatory HIV-infected persons for tuberculosis.
    Gounder CR; Kufa T; Wada NI; Mngomezulu V; Charalambous S; Hanifa Y; Fielding K; Grant A; Dorman S; Chaisson RE; Churchyard GJ
    J Acquir Immune Defic Syndr; 2011 Oct; 58(2):219-23. PubMed ID: 21765364
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Diagnostic accuracy of a rapid urine lipoarabinomannan test for tuberculosis in HIV-infected adults.
    Nakiyingi L; Moodley VM; Manabe YC; Nicol MP; Holshouser M; Armstrong DT; Zemanay W; Sikhondze W; Mbabazi O; Nonyane BA; Shah M; Joloba ML; Alland D; Ellner JJ; Dorman SE
    J Acquir Immune Defic Syndr; 2014 Jul; 66(3):270-9. PubMed ID: 24675585
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Severe adverse events during second-line tuberculosis treatment in the context of high HIV Co-infection in South Africa: a retrospective cohort study.
    Schnippel K; Berhanu RH; Black A; Firnhaber C; Maitisa N; Evans D; Sinanovic E
    BMC Infect Dis; 2016 Oct; 16(1):593. PubMed ID: 27769174
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Sensitivity of the lateral flow urine lipoarabinomannan assay in ambulant adults with advanced HIV disease: data from the TB Fast Track study.
    Tlali M; Fielding KL; Karat AS; Hoffmann CJ; Muravha T; Grant AD; Charalambous S
    Trans R Soc Trop Med Hyg; 2020 Aug; 114(8):556-560. PubMed ID: 32313941
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Systematic, Point-of-Care Urine Lipoarabinomannan (Alere TB-LAM) Assay for Diagnosing Tuberculosis in Severely Immunocompromised HIV-Positive Ambulatory Patients.
    Huerga H; Cossa L; Manhiça I; Bastard M; Telnov A; Molfino L; Sanchez-Padilla E
    Am J Trop Med Hyg; 2020 Mar; 102(3):562-566. PubMed ID: 31971152
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Urinary LAM grade, culture positivity, and mortality among HIV-infected South African out-patients.
    Kubiak RW; Herbeck JT; Coleman SM; Ross D; Freedberg K; Bassett IV; Drain PK
    Int J Tuberc Lung Dis; 2018 Nov; 22(11):1366-1373. PubMed ID: 30355418
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Diagnostic accuracy of the rapid urine lipoarabinomannan test for pulmonary tuberculosis among HIV-infected adults in Ghana-findings from the DETECT HIV-TB study.
    Bjerrum S; Kenu E; Lartey M; Newman MJ; Addo KK; Andersen AB; Johansen IS
    BMC Infect Dis; 2015 Oct; 15():407. PubMed ID: 26427365
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Performance of Tuberculosis Molecular Bacterial Load Assay Compared to Alere TB-LAM in Urine of Pulmonary Tuberculosis Patients with HIV Co-Infections.
    Mapamba DA; Sauli E; Lalashowi J; Buza J; John J; Mwaisango Z; Tarmo P; Sabi I; Rachow A; Ntinginya NE; Mtafya B
    Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36835127
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.